BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement in the journal, Neuro-Oncology (Neuro Oncol 2014 June; 16(Suppl 1): i1-i157). The abstract numbers are CT-004, HG-017, and MB-039.

Highlights from Abstract CT-004
The abstract title is "A phase II study of Antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on Protocol BT-22." Primary malignant brain tumors are the leading cause of cancer-related death in children. This single arm two-stage phase II study evaluated the efficacy and safety of combination of Antineoplastons A10 and AS2-1 (ANP) in children who developed progression of primary brain tumors during standard treatment. A total of 30 children who met the eligibility criteria were treated according to Protocol BT-22 at the Burzynski Clinic (BC). There were 8 cases of glioblastoma (GBM), 11 cases of diffuse intrinsic pontine glioma (DIPG), 6 cases of anaplastic astrocytoma (AA), 2 cases of primitive neuroectodermal tumors (sPNET) and 1 case each of atypical teratoid rhabdoid tumor (ATR), disseminated pilocytic astrocytoma, and medulloblastoma (PNET). Five patients (17%) obtained complete and partial responses; four patients were diagnosed with recurrent DIPG, and one with recurrent AA. The longest survivor is a patient diagnosed with DIPG and disseminated gliosarcoma who remains alive more than 14 years from the treatment start. A small group of patients reported serious toxicity including hypernatremia, somnolence, and hypokalemia.

It is concluded that antineoplastons showed efficacy within an acceptable profile in this group of patients with recurrent, refractory or progressive primary brain tumors.

Titles of Abstracts HG-017 and MB-039
Abstract HG-017: A long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report.

Abstract MB-039: Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report.

The abstracts are scheduled for presentation in the poster session on June 30, 2014 from 6 PM to 8 PM.


Burzynski Research Institute, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study finds substantial differences in cancer drug funding decisions across high-income countries